None listed
Conditions
Brief summary
The importance of long-chain omega-3 polyunsaturated fatty acids (LCn3PUFA) in fish oil is widely recognised for its ranging health benefits. More recently, studies have looked at metabolic effects of fish oils. An early study indicated that dietary fish oil supplementation reduces body fat mass and stimulates fat oxidation in healthy adults. Whilst associations have been found between LCn3PUFA and body composition, there is inconsistency between studies looking at weight loss. Recent human studies have shown that provision of EPA and DHA from fish oil in a dose-dependent manner correlates strongly with an increase in the omega-3 index. However, no study to date has administered fish oil in a dose-dependent manner based on weight and examined the effects on resting energy expenditure, fat oxidation and body fat. Employing such a method may provide more substantial evidence to support an inverse relationship between fish oil supplementation and weight loss.
Interventions
A double-blind, randomised, placebo-controlled intervention trial designed to evaluate whether fish oil supplementation can positively impact on metabolic rate in overweight women. Forty volunteers will be recruited through public advertisements. Prior to the commencement of the study volunteers will complete a series of questionnaires and tests designed to assess general health, diet history and exercise habits. Participants will be randomly allocated to consume 5 x 1g capsules per day containing either vegetable oil (control group) or fish oil for the duration of the study. Participants in the control group will receive 5 x 1g capsules of vegetable oil. For participants randomised to the fish oil group, the amount of fish oil provided will be based on participants’ total body weight. Participants will receive 2-5 fish oil capsules (each capsule of fish oil contains 600mg of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) with the remainder as vegetable oil, providing a total of 5 capsules per day. Possible combinations are therefore; Group 1: up to 65kg (BMI 25-27.5) --> 2 fish oil, 3 placebo, Group 2: 65.1-75kg (BMI 27.6-30) --> 3 fish oil, 2 placebo, Group 3: 75.1-85 (BMI 30.1-32.5) --> 4 fish oil, 1 placebo, Group 4: 85kg and over (BMI 32.6-35) --> 5 fish oil, no placebo. A supplement diary will be used to assess compliance. Participants will attend two study visits at baseline (week 0) and at completion of the intervention (week 6). During these visits each participant will have a series of non-invasive measurements taken which include height, weight, resting energy expenditure, fat oxidation and body fat. Blood samples will be collected at both visits and assessed for erythrocyte saturation of two key fatty acids, DHA and EPA
Sponsors
Study design
Eligibility
Inclusion criteria
1. Female 2. BMI between 25-35 kg/m2 3. Non-smoker (minimum 6 months of abstinence) 4. Weight stable (changes < 5kg) within the last 3 months
Exclusion criteria
1. Current smokers and ex-smokers within the last 6 months 2. Consume >1g fish oil supplement/day within the last 3 months 3. Have undergone anticoagulant therapy in the past 3 months 4. Are taking other anti-platelet agents; bleeding disorders 5. Have a cardiac condition (including high blood pressure), asthma, thyroid disorders, chronic disease 6. Have changed medication in the last 3 months 7. Take vitamin, mineral or herbal supplementation that may impact on study outcomes 8. Consume >4 cups coffee/day or a high level of caffeine that in the opinion of the investigators will be unsuitable for this study 9. Suffer claustrophobia or a fear of enclosed spaces 10. Have gained or lost weight (> 5kg) within the last 3 months 11. Are already involved in another research project within 30 days of commencement of the present study that in the opinion of the investigators will be unsuitable for this study 12. Are pregnant or breastfeeding (due to changes in metabolic rate) 13. Are allergic to fish or fish products